Two types of pathological alterations of EGFR in cancers, the kinase-activating mutation in EGFR and the overexpression of the EGFR protein, are common traits in many solid tumors and validated delivery targets for several cancers including lung, colorectal, and certain subtypes of breast cancer [69]. This evidence concerns the gene EGFR and cancer.